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Abstract
Background: The contribution of alternative splicing and isoform expression to cellular response is emerging as an
area of considerable interest, and the newly developed exon arrays allow for systematic study of these processes.
We use this pilot study to report on the feasibility of exon array implementation looking to replace the 3’ in vitro
transcription expression arrays in our laboratory.
One of the most widely studied models of cellular response is T-cell activation from exogenous stimulation. Micro-
array studies have contributed to our understanding of key pathways activated during T-cell stimulation. We use
this system to examine whole genome transcription and alternate exon usage events that are regulated during
lymphocyte proliferation in an attempt to evaluate the exon arrays.
Results: Peripheral blood mononuclear cells form healthy donors were activated using phytohemagglutinin, IL2
and ionomycin and harvested at 5 points over a 7 day period. Flow cytometry measured cell cycle events and the
Affymetrix exon array platform was used to identify the gene expression and alternate exon usage changes. Gene
expression changes were noted in a total of 2105 transcripts, and alternate exon usage identified in 472 transcript
clusters. There was an overlap of 263 transcripts which showed both differential expression and alternate exon
usage over time. Gene ontology enrichment analysis showed a broader range of biological changes in biological
processes for the differentially expressed genes, which include cell cycle, cell division, cell proliferation,
chromosome segregation, cell death, component organization and biogenesis and metabolic process ontologies.
The alternate exon usage ontological enrichments are in metabolism and component organization and biogenesis.
We focus on alternate exon usage changes in the transcripts of the spliceosome complex. The real-time PCR
validation rates were 86% for transcript expression and 71% for alternate exon usage.
Conclusions: This study illustrates that the Exon array technology has the potential to provide information on
both transcript expression and isoform usage, with very little increase in expense.
Background
Transcriptional analysis using microarray technology has
provided key insights into the biologic processes
involved in lymphocyte proliferation and activation
[1-10]. While changes in alternative splicing has also
recently been recognized to critically influence these
processes [11,12], it has been technically quite challen-
ging to conduct these studies. A new generation of
arrays with sufficient feature density to target every
known and predicted exon in the human genome has
been developed. These exon arrays have the potential to
allow the examination of transcript changes combined
with alternate exon usage in response to specific stimuli.
In addition to changes in design of the Exon arrays
compared to the previous generation 3’ in vitro transcrip-
tion (IVT) arrays [13], significant differences in protocols
for their use present challenges to laboratories interested
in switching platforms. These include RNA labeling
methodologies [14], detection calling [15], quality control
checks for labeling [16] and CEL file assessment [17], and
analytical methodologies [18,19]. We designed a small
study to assess exon array implementation and develop
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any medium, provided the original work is properly cited.best laboratory practices and expertise to facilitate adop-
tion of this technology. This study examines T-cell
responsiveness to stimulation with pharmacologic mimics
of antigen-receptor signaling with the intent to examine
mRNA alternative splicing and transcript expression dur-
ing proliferation. This model system was selected because
methods for activating or differentiating lymphocytes are
well understood and the cells can be readily cultured.
Most importantly perhaps, comprehensive gene expres-
sion profiles have been published allowing cross platform
comparisons [20,21].
Methods
Subjects
Blood samples were obtained from 4 healthy Caucasian
female volunteers, age 46-56 years. Allergies and hay
fever were excluded by self-report. Informed consent
was obtained from all subjects, and human experimenta-
tion guidelines of the US Department of Health and
Human Services were followed in the conduct of this
research.
Primary cell isolation and stimulation
Whole blood was collected from each donor in 20 cell
preparation tubes (sodium citrate, Becton Dickinson,
CA) and the peripheral blood mononuclear cells
(PBMCs) purified according to the manufacturer’s
instructions. Lymphocytes for each donor were pooled,
counted, assessed for viability with trypan blue (>98% in
all cases), frozen and stored in liquid nitrogen.
Just prior to use the PBMCs from each donor were
fast thawed at 37°C and seeded into 5 T25 flasks (one
for each time point) at 1.425 × 10
7 cells in 14.25 mL
Roswell Parks Memorial Institute 1640 (RPMI) medium
containing 20% fetal bovine serum. A T25 flask was har-
vested and assessed at day 0 (prior to stimulation, D0).
Cells in all other flasks were stimulated by the addition
of phytohemagglutinin (PHA, 1 μg/mL), Interleukin-2
(IL2, 10 U/mL) and ionomycin (1 μM). Flasks, one from
each donor, were harvested and assayed on D1, D3, D5
and D7. Cell counts were performed using trypan blue
and samples were split for the individual assays. Flow
cytometric analyses were done at the time of harvesting,
and the 4 × 10
6 cells were pelleted, resuspended in 1 ml
TRIzol reagent (Invitrogen, CA) and frozen for microar-
ray analysis.
Flow cytometric analysis
Immunophenotyping was performed at each time point
on 5 × 10
5 cells to determine the T-cell (CD3-PerCP-
Cy5.5), B-cell (CD19-phycoerythrin) and NK cell
(CD56-AlexaFluor488, CD16-FITC) subsets. The assay
also included activation markers CD69-allophycocyanin
(APC) and CD25-APC. Briefly, samples were incubated
with appropriate concentrations of monoclonal antibo-
dies (Becton Dickinson, San Jose, CA) for 30 minutes at
room temperature in the dark. Cells were then fixed in
4% paraformaldehyde for 10 minutes at 37°C and stored
at 4°C until flow cytometric analysis. A second tube of
5×1 0
5 cells was stained for the TUNEL assay using the
APO-BrdU kit (BD Pharmingen) as recommended by
the manufacturer. After assay completion, Hoechst
33342 was added for cell cycle determination and imme-
diately processed on the flow cytometer. Typically
50,000 events were collected. Data was acquired using
CellQuest software (version 3.3) (BD Biosciences). Com-
pensation for the assays and all data analysis was
performed using FlowJo software (version 7) (TreeStar,
Ashland, OR).
Microarray procedures
Total RNA was extracted from the PBMCs in TRIzol
reagent according to the manufacturer’s instructions
and quality and quantity was assessed using the Agilent
2100 Bioanalyzer. One μg was labeled using the Exon
WT Sense Target Labeling Assay (Affymetrix®, Santa
Clara, CA) including the labeling controls from the
GeneChip® Eukaryotic Poly-A RNA Control Kit. Each
step of the labeling protocol was monitored using either
the Agilent 2100 Bioanalyzer or the Nanodrop spectro-
photometer, as specified by Affymetrix [14]. Quality
control (QC) criteria included: 1) after the first cycle
cRNA cleanup yields >10 μg as measured by Nanodrop;
2) after the second cycle single-strand cDNA cleanup,
yields >5.5 μg. Both checkpoints need OD260/280 ratios
of 1.8 - 2.2; 3) required the fragmented antisense biotin-
labeled cDNA to peak at 40-70 bases when run on the
Bioanalyzer. Hybridization buffer, Eukaryotic Hybridiza-
tion Controls (to confirm the sensitivity of hybridiza-
tion), and OligoB2 controls (used to orient and grid the
array) were added to the cDNA fragments just prior to
hybridization to the Affymetrix® Human Exon 1.0 ST
Array. Hybridization was at 45°C for 17 hours [14]. Fol-
lowing hybridization, the chips were washed and stained
with a phycoerythrin-strepavidin conjugate using the
GeneChip® Fluidics Station with the FS450-0001 proto-
col. The chips were scanned using the Affymetrix® Gen-
eChip® Scanner 3000 and the Affymetrix® GeneChip®
Operating Software was utilized for the management,
sharing and initial processing of the expression data. All
data from the 20 exon arrays has been deposited in
Array Express under Accession Number E-MEXP-884.
Array quality control was performed using Affymetrix®
Expression Console™ (v 1.1) at the transcript level using
core-level probe sets. All image plots passed visual
inspection. Hybridization controls had all present with
signal increases following concentration. Labeling con-
trol signal strengths followed the order Lys < Phe < Thr
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for raw and processed data. These provided a meaning-
ful way to identify arrays with divergent probe intensity
distributions relative to other arrays in the study. The 3
summarization metrics relative log expression (RLE),
positive vs. negative ROC AUC and MAD-residual
mean were all within the parameters suggested by Affy-
metrix [16,17].
Data preparation and analysis
Data was pre-processed using Partek Genomic Suite
software ((v6.4) Partek Inc., St. Louis, MO) with the
core meta-probe set. The configuration consisted of a
pre-background adjustment for GC content and probe
sequence, Robust Multi-array Analysis [22] for back-
ground correction, quantile normalization and probe set
summarization using median polishing. All signals were
log2 transformed. Library files were those specified by
Affymetrix (HuEx-1_0-st-v2) and the annotation file
version was na29.hg18.
The data analysis workflow for exon arrays is two
pronged [18]. For determination of differential expres-
sion, probe set information is summarized into gene
level information, and the analytical methodologies
remain unchanged from those used for 3’ IVT array
data. Differential expression was calculated using a
repeated measure ANOVA with Time as the main
effect. The multiple test correction implemented the
q-value method [23] to determine a false discovery rate
(FDR) < 0.0001.
A second analysis looks at exon level data. In order to
obtain meaningful alternate exon usage information, and
to decrease the chance of false positives, several filtering
steps were included prior to analysis [24]. The presence
of absence of exon expression was determined using
detection above background (DABG). All probe sets
where the DABG p-value < 0.05 were removed from the
analysis. All genes represented by fewer than 5 probe
sets in the transcript cluster were removed as it is often
difficult to interpret alternative exon incorporation pat-
terns with so few markers. Similar reasoning was used
to remove genes represented by >40 probe sets. All
transcript clusters with high differential exonic expres-
sion (> 5-fold change) between groups were removed, as
they have a tendency to produce false positive results
for alternative splicing [18]. Data were analyzed for
alternative splicing by a repeated measure ANOVA with
Time × Probe set as the main effect and corresponding
interaction. Pair-wise analyses between D0 and the
other time points were also performed. It is not clear
how best to correct for multiple testing for the alterna-
tive-splicing analysis, however, the optimal cutoff value
is dependent on the number of targets you wish to see
in your final list. The q-value method was used to
control the FDR with a cutoff <0.0001 to determine the
presence of alternative exon usage. Several investigators
have previously suggested that manual review of the
gene plots is required to identify forms of alternative
splicing and determine the frequency of changes
observed in the dataset [18,25,26]. Criteria used
for assessment were the same as those described
previously [24].
Biological interpretation
Gene enrichment analysis was used to interpret the bio-
logical impact of alternative exon usage and differential
expression during lymphocyte proliferation. Gene Ontol-
ogy (GO) enrichment analysis was undertaken in Partek
Genomic Suite using a chi-square test comparing the
proportion of the transcript list in an ontology, to the
proportion of the background list in that same ontology.
Functional groups with >5 genes and an enrichment
score > 3 were considered significant.
Exon array validation by Quantitative real-time
polymerase chain reaction (qPCR)
Exon array findings (both expression and alternate exon
usage) were validated using qPCR on the seven genes
focused on in this study (additional file 1). Validation of
alternate exon usage was performed using 2 different
primer-probe combinations within the same transcript.
One pair to an area that showed isoform variation (D),
and a second to an area which showed none (referred to
as the “control” (C) primer-probe set). The latter was
used as an endogenous normalizer. For transcript
expression validation b-Actin was the normalizer gene
with the C primer-probe set for the transcript of inter-
est. b-Actin expression did not vary significantly across
the samples, allowing it to be used as the normalizer.
Primer Express software (version 2.0) was used for the
primer-probe design with transcript sequences from the
NetAffx website. Probes were 5’ labeled with 6-carboxy-
fluorescein (FAM) and 3’ labeled with MGB (minor
groove binder) non-fluorescent quencher. Information
on primers and probe sets used are in additional file 1.
PCR amplification efficiencies (E = 10
-1/slope) were deter-
mined using a 5-step 5 fold dilution standard curve
(10 ng to 16 pg) and PBMC total RNA. Initial optimiza-
tion experiments showed all PCR products were single
bands by agarose gel electrophoresis and calibration
curves (plotting relative concentrations against the
threshold cycle (Ct)) had RSq values (an indicator of
line fit) > 0.99 for all primer pairs. Based on the slopes
of the standard curves, the amplification efficiencies
ranged from 1.8 to 2.0 (additional file 1).
One microgram of RNA was reverse transcribed into
cDNA using random hexamers. The 20 μL qPCR reac-
tion contained 1 × ProbeMaster PCR Master Mix
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and 5 μL template. The cycling conditions consisted of
one cycle at 95°C for 5 min followed by 45 cycles of
95°C × 15 s, and 60°C × 30 s, on the Lightcycler® 480
system (Roche Applied Science, IN). All samples, includ-
ing standards and non-template control were run in
triplicate. The Lightcycler® 480 software (version 1.50)
was used for data analysis. For comparative quantifica-
tion the ΔΔCt method was applied [27,28] as it is suita-
ble for a quick estimation of the relative expression
ratio. This model presumes optimal and identical ampli-
fication efficiencies of target and reference genes.
Results
Exon labeling and microarray quality control assessment
The total RNA extracted from PBMCs had RINs > 8.5
and 1 μg was used for rRNA reduction. The percentage
reduction ranged from 53-78%, with D0 unstimulated
specimens showing an average reduction of 56%, D1
69%, D3 and D5 67%, and D7 61%. The averaged % pre-
sent calls on the array data were 52, 52 45, 49 and 50
respectively. Quality control check-points outlined in
the methodology were easily met. The average yield for
the cRNA step ranged from 18.5 to 65.4 μga n dt h e
cDNA from 10.4 to18.9 μg. In both cases the lesser
quantities were for D1 specimens. All yields were double
that required for the next step, and OD260/280 ratios
were around 2. After fragmentation the peak size was
consistently between 70 and 80 bases. The array QC
metrics met all those specified in the Affymetrix refer-
ence card [16].
Data filtration
For the expression data all probe sets with a log2 signal
< 3 were removed, leaving 126,110 probe sets which
summarized to 15,395 transcript clusters. For the alter-
nate exon usage analysis, several layers of filtration were
used to reduce the number of tests and increase the
detection of alternative splicing events [24]. After filtra-
tion the data set covered around 3,700 transcripts.
Lymphocyte stimulation
Stimulation resulted in reduced B- and NK-cell popula-
tions, with marked increases in the number of T-cells
(Figure 1A). T-cells represent >85% of the cell popula-
tions from D3 onward. Up-regulation of cell surface
markers CD69 and CD25 reflect the early and late acti-
vation of lymphocyte populations respectively (Figure
1B). Activation was first noted by D1 reaching a peak
on D3 for NK-, T-, and B-cells, each population show-
ing activation in 70-80% of the population. Total cell
numbers decreased from D0 to about 40% for D1 and
D3, and then increased on D5 and D7 to 140% of
baseline. Stimulated cell viability remained around 90%
throughout the time series.
Flow cytometric analysis showed the cell cycle position
(Figure 2A) and apoptotic status (Figure 2B) of the lym-
phocyte population across the proliferation assay.
A major shift into the S phase was seen by D3, with a
small proportion of lymphocytes being at G2/M, all
returning to G0/G1 by D5 (Figure 2A). These assays pro-
vide good markers for interpreting the differential
expression and alternate exon usage data derived from
the exon arrays. We are able to overlay biological
changes measured by different platforms relating to cell
cycle, validating what is being measured by the exon
array platform.
Exon analysis: Alternate exon usage
Both alternative exon usage and transcript expression
profiling were assessed over the 7 days of lymphocyte
stimulation. The splice-variant ANOVA exploring alter-
nate exon usage changes over time identified 658 tran-
script clusters with alternate exon usage after multiple
test correction (q-value < 0.0001). Visual inspection [24]
recognized 472 transcript clusters as likely candidates.
Pair-wise analyses comparing each day to the baseline
unstimulated cells (D0) identified 641 unique transcript
clusters with alternate exon usage after visual inspection.
Venn diagrams show the distribution and overlap of
these transcript clusters (Figure 3.)
The 204 transcript clusters showing alternate exon
usage within 24 hours of stimulation (D1; Figure 3) were
statistically enriched for regulation of signal transduction
(18 transcripts). Ten are involved in GTPase mediated
signal transduction (see additional file 2), which involves
both Ras and Rho subfamilies. Activation of these signal-
ing pathways results in cell growth, differentiation and
survival, which are reflected in the D1 enrichment analy-
sis by ontologies for cell differentiation (17 transcripts)
and cell death (20 transcripts). Half of the transcripts
enriched in the cell death ontology are involved in its
negative regulation. Other alternate exon usage changes
evident at D1 are two metabolism related categories:
Eicosanoid (4 transcripts) and RNA metabolism (20 tran-
scripts, 9 are involved in RNA splicing). D3 alternate
exon usage enrichment analysis show RNA metabolism,
leukocyte differentiation, and cell death ontologies. How-
ever, few transcripts in each category overlap with D1
indicating the dynamics of alternate exon usage are chan-
ging. For example, D1 has 9 transcripts associated with
RNA splicing and D3, 13. Four are shared between the
days (PRPF31, SFRS2, SFRS10 and SFRS10). D3 shows
enrichment in signal transduction terms, dominated by
T-cell receptor signaling (2 transcripts) and protein
kinase cascade (17 transcripts). The later continues
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nuclear transport (9 transcripts, 6 in mRNA export),
positive regulation of transcription (9) and DNA repair
(13). The latter extends to the D5 (13) and D7 (13) ana-
lyses. Three transcripts are common to DNA repair over
this time, whereas 6 are unique to D3, 5 to D5 and 5
transcripts to D7 (additional file 2).
Approximately 50% of transcripts showing alternate
exon usage across the time series are associated with
cellular metabolism.
Exon analysis: Transcript expression
A parallel analysis identified 2105 unique transcript
clusters as differentially expressed (after multiple test
correction) during the seven days of lymphocyte stimu-
lation compared to D0. Of these, only 263 (12.5%) also
showed alternate exon usage.
Functional comparison of alternate exon usage and
differentially expressed transcript lists
Enrichment analysis of the statistically significant tran-
script lists compared to those on the array was per-
formed. Examination of “cellular process” in the GO
biological process hierarchy (Table 1) allowed us to focus
on changes in cell cycle and apoptosis, enabling compari-
son to the flow cytometric data. Differentially expressed
transcripts show a much broader functional role com-
pared to those having alternate exon usage. They are
enriched in cell cycle, cell division, cell proliferation,
chromosome segregation, cell death, component organi-
zation and biogenesis and metabolic process ontologies
(Table 1). The enrichment of the alternate exon usage
transcript lists only shares the last 2 ontologies.
Alternate exon usage in transcripts involved in nuclear
mRNA splicing via the spliceosome
For the transcripts showing alternate exon usage, RNA
processing was a dominant ontology, with nuclear
mRNA splicing via the spliceosome being an enriched
sub-category. This GO contains 101 transcripts, of
which 8 showed alternate exon usage (SFRS2, SFRS7,
SFRS10, RBM25, U2AF2, SNRPB, PRPF31 and DDX39).
The 3 last transcripts also had statistically significant
differential expression (Figure 4A), and a further 15
transcripts showing differential expression only were
identified in this ontology.
Several arginine/serine rich splicing factors show dif-
ferent alternative exon usage profiles after lymphocyte
Figure 1 Results of flow cytometric analysis of PBMC subsets. T lymphocytes (CD3
+), B lymphocytes (CD19
+) and NK cells (CD16
+ CD56
+)
showing the averaged percentage of counted events ± standard deviation attributed to each subset (A), and the activation status of each
subset determined by CD25 and CD69 status as a % of cell subset numbers ± standard deviation (B).
Figure 2 Cell cycle (A) and apoptotic (B) distribution of lymphocytes after PHA stimulation as determined by flow cytometry. Cell cycle
progression was monitored in PHA-stimulated lymphocytes at indicated times by Hoechst 33342 staining and TUNEL assay for apoptotic status.
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Page 5 of 13stimulation. SFRS2 has four mid-transcript probe sets
with significantly higher exon expression on D0 (Figure
5) indicating an increase of the retained intron in unsti-
mulated lymphocytes. SFRS7 shows a mix of mRNA iso-
forms across the time series (Figure 5) with a cassette
exon being highly expressed in unstimulated lympho-
cytes and decreased inclusion after stimulation. All
other core-meta probe sets have similar expression
levels on all days. Visualization with the full meta-probe
set (to give a clearer picture) indicates 3 areas in SFRS7
with intron retention not described in the UCSC data
base (Figure 5). SFRS10 shows statistical significant dif-
ferences in the exon expression of probe set 2709102 on
D1 and D3 relative to D0 (Figure 6). This is confirmed
by similar expression patterns for the 7 adjacent probe
sets included from the full meta-probe set. Expression
levels for the 26 remaining probe sets are the same for
all days (Figure 6).
SNRPB (small nuclear ribonucleoprotein polypeptides
B and B1) shows major differences in exon expression
after stimulation in 5 probe sets at the 3’ end of the
transcript (Figure 6). This covers an overlapping or
“bleeding” exon described in the UCSC AltEvent track
descriptor [29].
RBM25 (RNA binding motif protein 25) is represented
by 15 core meta-probe sets focused on the smallest
mRNA isoform (Figure 7). Exon expression levels are
statistically significant for 3 probe sets of the 3’ cassette
exon between D0 and D3. The full meta-probe set adds
28 probe sets belonging to 2 long isoforms. Signal for
intronic sequence probe sets (3543455-3543456)
indicates intron inclusion, which decreases during cell
cycle progression (Figure 7).
U2AF2 (U2 small nuclear RNA auxiliary factor 2)
shows different exon expression patterns at each end of
the transcript. The 6 probe sets of the 5’ exon show no
differential expression, but all probe sets thereafter show
differential expression (Figure 7). No expression is noted
from probe sets to intronic regions.
Gene view diagrams for PRPF31 and DDX39 are given
in additional file 3.
RT-PCR validation of differential transcript expression and
transcript alternate exon usage
Validation was performed on 7 of the 8 transcript
clusters discussed above. DDX39 was not included
because of difficulties with primer/probe design. Two
levels of validation were attempted. The first exam-
ined transcript expression across the time series, nor-
malizing expression values to an external gene b-
Actin. Six of seven genes were validated, with the
microarray results being concordant to the qPCR data
in terms of direction of fold changes (Fig. 4A and 4B
respectively). Alternate exon usage was validated
using an internal transcript area with no differential
expression as the normalizer gene. Results reflect the
same abundance changes in the area of alternate exon
usage (Figure 8) as was evident on the exon arrays
(Figure 5, 6, 7). Five of seven events validated (71%).
Cross-validation with existing information on alter-
nate exon usage is also extremely useful. We have
overlaid the UCSC genome browser AltEvent track
onto the relevant gene views (Figure 5, 6, 7). This
s h o w sv a r i o u st y p e so fa l t e r native splicing, including
alternative promoter usage, cassette exons etc. that
result in more than a single transcript. Many of these
were concordant with our findings but several events
appear to be newly described.
Discussion
The Affymetrix exon arrays offer a significant increase
in content and a greater utility than their 3’ expression
arrays. The distribution of probes sets across each exon
for some 28,800 genes allows the mapping of splice var-
iants. They feature a new design with no mismatch
probes, and a random primed protocol to generate
sense DNA targets along the entire length of the tran-
script. These changes raised uncertainty with regard
array performance, but transcript expression has been
shown comparable with the 3’ platforms with close
agreement and similar sensitivity [30-32]. The minimal
price difference between the platforms makes the exon
array an attractive alternative. This pilot study was
designed to determine the practicality of implementing
these arrays in our laboratory.
Figure 3 Venn diagram of transcript clusters with alternate
exon usage. Alternate exon usage identified for transcript clusters
by pair-wise ANOVA relative to D0 and confirmed by visual
inspection.
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Page 6 of 13Table 1 Enrichment analysis in GO of transcripts from alternate exon usage and differential expression analysis of lymphocyte proliferation
Analysis Compare
to D0
No. significant
transcript
Cell cycle
process
Cell
cycle
Cell
division
Metabolic
process
Chromosome
segregation
Cellular organization and
biogenesis
Cell
proliferation
Cell
death
Cell
adhesion
Cell
communication
No. genes in category 376 381 234 3599 25 924 278 417 620 527
D1 204
D3 359 108 20
AEU D5 288 13 9 80 26
D7 256 11 75 24
Time 472 121 39
D1 621 30 161 17 25
D3 1855 116 119 80 499 12 137 57 66 35 34
DE D5 880 76 84 61 207 11 68 33 30
D7 818 66 68 52 196 10 64 32 32
Time 1980 120 116 82 518 13 153 53 68 39
Gene Ontology (GO) enrichment analysis of transcript lists was undertaken in Partek Genomic Suite. Results are presented for Cellular Process category under the GO Biological Process. Groups are presented with an
enrichment score > 3 and > 5 genes per group.
AEU: alternate exon usage
DE: Differential expression
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from reagents and protocols to quality control and
analysis software is different for the exon arrays com-
pared to the previous 3’ arrays. Both labeling meth-
odologies take approximately 2 1/2 days with 2
overnight steps (an in vitro transcription step followed
by hybridization on the second night.) However, the
Exon protocol has more steps and requires consider-
ably more hands-on time (we estimate double), espe-
cially on the second day. A ribosomal RNA reduction
step is required prior to RNA labeling to reduce their
impact on amplification and labeling because of the
random prime labeling strategy. This necessitates the
purchase of special equipment for the magnetic bead
separation. A scanner autoloader is also required as
scan times increased from 12 to 30 minutes per Gene-
Chip with the change in platform. In our laboratory
we were able to do manual labeling of 8 samples per
run, whereas for the 3’ arrays we could do 24. The
downstream processing of data is also a challenge.
Data sets are much larger and the analysis is per-
formed at several different levels: exon (for alternate
splicing) or transcript (for expression levels) using
either the core, full or extended probe sets [13].
The quality control checks for monitoring the labeling
protocol and the hybridized GeneChip were extremely
useful. The former could save running poor samples on
an array, allowing the labeling to be repeated. The latter
prevented the inclusion of technical outliers in the sta-
tistical analysis. All our samples easily met the QC cri-
teria. The only disparate data were differences in %
rRNA reduction. D0 samplesh a dt h el o w e s ta v e r a g e
reduction (56%), peaking on D1 (69%) and returning to
baseline with D3 and D5 at 67%, and D7 at 61%. These
differences were most likely due to increased protein
synthetic levels expected for cell proliferation.
The corroboration of both transcript expression and
alternate exon usage data using a different analytical
platform adds weight to the value of exon arrays as an
analytical tool. Our validation rates by real-time PCR
were 86% for expression data, and 71% for alternate
exon usage results. Validation rates for alternate exon
usage in other studies using Affymetrix exon arrays
range from 21 to 84% [33-35], some of the fluctuation
can probably be attributed to differences in data filtra-
tion and no visual inspection of the results, emphasizing
the importance of best practice methodologies. The
alternate exon usage in many of the transcript clusters
identified in this study showed greater complexity than
a single exon inclusion or exclusion event, illustrating
that more than one alternative splice isoform can be
maintained concurrently in the mRNA pool. For this
data set, it is not possible to dissect if this reflects
changes in the ratios of isoforms associated with physio-
logical variation or reflect changes in the cell sub-popu-
lations. It is estimated that more than 75% of genes
produce alternative transcripts [36,37], contributing to
functional diversity in the genome. Therefore there is
little question that this is an important component of
understanding the complexity of the mammalian
transcriptome.
Implementation of the Affymetrix exon arrays requires
a considerable input of time but our results show that
the benefits are worth the effort. Probably the most
challenging area currently, is the downstream analysis of
data, mainly because of the increased data set size.
Much work has been done to characterize the genome-
wide transcriptional program of lymphocyte activation
and proliferation in a wide range of systems, including
cell culture [38] whole blood [39], PBMCs [40] and puri-
fied cell populations [38,41,42]. This is a critical step
toward understanding the biologic processes involved.
Figure 4 Expression profiles of transcripts involved in nuclear mRNA splicing via the spliceosome. (A) Changes in transcript expression
levels from exon array data. (B) Validation of array expression data by qPCR. All data is presented relative to D0 baseline.
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Page 8 of 13Figure 5 Transcript cluster gene views showing alternate exon usage by day of proliferation for SFRS2 and SFRS7. The LS mean log2
signal intensity (with standard error bars) for each day is plotted against the full meta-probe set of the transcript. An asterisk (*) denotes probe
sets belonging to the core data set, used for analysis, when colored red this indicates statistical significance for alternate exon usage. The top
half of the graph shows all known isoforms in this region retrieved from the UCSC browser, the location (above or below the line) defines which
DNA strand codes for the transcript. In the alternate location UCSC AltEvent information is given. A green rectangle indicates a bleeding exon;
blue a retained intron; and red a cassette exon. Previously described events are highlighted by a grey box and possible new events are denoted
by a hatched grey box. Parallel expression lines indicate that the transcript is not differently spliced in the groups. C or D designates the control
or differential primer-probe set location for result validation
Whistler et al. BMC Genomics 2010, 11:496
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Page 9 of 13Figure 6 Transcript cluster gene views showing alternate exon usage by day of proliferation for SFRS10 and SNRPB. The LS mean log2
signal intensity (with standard error bars) for each day is plotted against the full meta-probe set of the transcript. An asterisk (*) denotes probe
sets belonging to the core data set, used for analysis, when colored red indicates statistical significance for alternate exon usage. The top section
of the graph shows all known isoforms in this region retrieved from the UCSC browser, the location (above or below the line) defines which
DNA strand codes for the transcript. In the alternate location UCSC AltEvent information is given. A green rectangle indicates a bleeding exon;
blue a retained intron; orange an alternative 3’ start site; and red a cassette exon. Previously described events are highlighted by a grey box and
possible new events are denoted by a hatched grey box. Parallel expression lines indicate that the transcript is not differently spliced in the
groups. C or D designates the control or differential primer-probe set location for result validation.
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Page 10 of 13Figure 7 Transcript cluster gene views showing alternate exon usage by day of proliferation for RBM25 and U2AF2. The LS mean log2
signal intensity (with standard error bars) for each day is plotted against the full meta-probe set of the transcript. An asterisk (*) denotes probe
sets belonging to the core data set, used for analysis, when colored red indicates statistical significance for alternate exon usage. The top section
of the graph shows all known isoforms in this region retrieved from the UCSC browser, the location (above or below the line) defines which
DNA strand codes for the transcript. In the alternate location UCSC AltEvent information is given. An orange rectangle indicates an alternative 3’
start site; and red a cassette exon. Previously described events are highlighted by a grey box and possible new events are denoted by a hatched
grey box. Parallel expression lines indicate that the transcript is not differently spliced in the groups. C or D designates the control or differential
primer-probe set location for result validation
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Page 11 of 13The interpretation of expression patterns from mixed cell
populations is complicated by variation in relative pro-
portions of the cell subsets. We cannot distinguish
between genes that undergo modest changes in a large
percentage of cells from those that undergo large changes
in a small subpopulation of cells. However, the strength
of using mixed cell populations is in considering the
interactions of these populations. Regulatory functions
may be provided by direct cell-to-cell contact or via cyto-
kine secretion from different cells. To understand the
regulatory networks underpinning cellular dynamics both
purified and mixed-cell populations need to be studied.
The same confounders apply to exon array profiling
along with the possible differential compartmentalization
of nuclear and cytoplasmic isoforms [43].
The majority of transcripts that showed differential
expression over time did not show a change in alternate
exon usage (87.5%), indicating that distinct networks of
regulation are operating. Interestingly, transcripts invol-
ving constitutive and alternative splicing regulators (the
SR family proteins [40] such as SFRS2, SFRS7 and
SFRS10) were significantly enriched for alternate exon
usage indicating auto-regulatory organization at the level
of transcript splicing. While most of the alternate exon
usage events in this study have previously been described,
several new splicing patterns were identified, another
benefit to implementing the exon array platform.
Conclusions
The ability to assess the functional state of lymphocytes
is important as it relates directly to the ability of people
to mount an effective immune response. Differences in
transcript abundance are routinely used as indicators of
cell activity, and this study shows that both transcript
quantity and isoform diversity contribute to the expres-
sion complexity of cells. Strategies examining multiple
forms of transcript expression changes are likely to pro-
vide a broader definition of cell behavior than are stu-
dies aimed at singular expression responses. We have
demonstrated the utility of the Affymetrix exon arrays
and we believe their implementation, in place of expres-
sion only platforms, will alter the way we interpret
microarray data. As an example, in this study we see dif-
ferent exon usage patterns in several proteins that play a
substantial role in regulating alternative splicing by
modulating spliceosome assembly and splice site choice
[44] after lymphocyte stimulation. This indicates that
alternative exon usage plays an important role in lym-
phocyte proliferation. These results highlight the need
for a more rounded view of expression analysis, and
show that an extra level of molecular diversity can be
added to studies with only a minor increase in cost.
Additional material
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Additional file 3: Gene view. Gene view plots for PRPF31 and DDX39.
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Figure 8 Validation of alternate exon usage array data by
qPCR. Two primer-probe sets were designed for each transcript,
one to an area of constant expression (control, C), the second to
region showing alternate exon usage (D). Comparative
quantification was calculated using the ΔΔCt method with the
control primer data being used as the endogenous normalizer. Ct
levels are inversely proportional to the amount of target RNA in the
sample. Comparison of daily profiles with signal intensities in Figure
5-7 shows good result concordance.
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